Efficacy and Safety of Pregabalin and Gabapentin for Pruritus: A Systematic Review and Meta-Analysis

IF 3.2 2区医学 Q2 CLINICAL NEUROLOGY

Journal of pain and symptom management Pub Date : 2025-01-01 DOI:10.1016/j.jpainsymman.2024.08.028

Wenting Xu MD , Hanyue Dong MD , Haolong Ran MD , Huan Liu MD , Lin Wang MD , Hongmin Li MD, PhD , Cheng Tan MD, PhD

{"title":"Efficacy and Safety of Pregabalin and Gabapentin for Pruritus: A Systematic Review and Meta-Analysis","authors":"Wenting Xu MD , Hanyue Dong MD , Haolong Ran MD , Huan Liu MD , Lin Wang MD , Hongmin Li MD, PhD , Cheng Tan MD, PhD","doi":"10.1016/j.jpainsymman.2024.08.028","DOIUrl":null,"url":null,"abstract":"<div><h3>Context</h3><div>Limited data existed on the efficacy and safety of novel antiepileptic drugs (pregabalin and gabapentin) in treating pruritus.</div></div><div><h3>Objectives</h3><div>To assess their role in managing either acute or chronic pruritus.</div></div><div><h3>Methods</h3><div>A systematic search was conducted in PubMed, EMBASE, the Cochrane Library, and Web of Science databases for relevant randomized controlled trials. Pooled odd ratio (OR) with 95% CI were performed using RevMan5.4 and R4.3.1.</div></div><div><h3>Results</h3><div>Analysis of 27 articles involving 2,016 patients showed significant reduction in pruritus incidence (OR, 0.30 [CI, 0.22–0.4]; I<sup>2</sup>=1%) and improvements in VAS (MD, 2.76 [CI, 0.95–4.57]; I<sup>2</sup>=98%) and 5-D scores (MD, 3.42 [CI, 2.10–4.75]; I<sup>2</sup>=92%) with pregabalin/gabapentin compared to controls. Adverse effects mainly included dizziness, somnolence, nausea and vomiting, dry mouth, constipation, and anxiety, with no significant difference between the groups (OR, 1.08 [CI, 0.32–3.59]; I<sup>2</sup>=76%).</div></div><div><h3>Conclusion</h3><div>The novel antiepileptic drugs pregabalin and gabapentin demonstrated significant therapeutic value in the treatment of pruritus, with a favorable safety profile. Compared to commonly used pruritus treatments such as antihistamines and antidepressants, these medications offered a promising alternative.</div></div>","PeriodicalId":16634,"journal":{"name":"Journal of pain and symptom management","volume":"69 1","pages":"Pages 65-81"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pain and symptom management","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0885392424009618","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Context

Limited data existed on the efficacy and safety of novel antiepileptic drugs (pregabalin and gabapentin) in treating pruritus.

Objectives

To assess their role in managing either acute or chronic pruritus.

Methods

A systematic search was conducted in PubMed, EMBASE, the Cochrane Library, and Web of Science databases for relevant randomized controlled trials. Pooled odd ratio (OR) with 95% CI were performed using RevMan5.4 and R4.3.1.

Results

Analysis of 27 articles involving 2,016 patients showed significant reduction in pruritus incidence (OR, 0.30 [CI, 0.22–0.4]; I²=1%) and improvements in VAS (MD, 2.76 [CI, 0.95–4.57]; I²=98%) and 5-D scores (MD, 3.42 [CI, 2.10–4.75]; I²=92%) with pregabalin/gabapentin compared to controls. Adverse effects mainly included dizziness, somnolence, nausea and vomiting, dry mouth, constipation, and anxiety, with no significant difference between the groups (OR, 1.08 [CI, 0.32–3.59]; I²=76%).

Conclusion

The novel antiepileptic drugs pregabalin and gabapentin demonstrated significant therapeutic value in the treatment of pruritus, with a favorable safety profile. Compared to commonly used pruritus treatments such as antihistamines and antidepressants, these medications offered a promising alternative.

查看原文本刊更多论文

普瑞巴林和加巴喷丁治疗瘙痒症的有效性和安全性：系统回顾和荟萃分析。

背景：有关新型抗癫痫药物（普瑞巴林和加巴喷丁）治疗瘙痒症的有效性和安全性的数据有限：评估这两种药物在治疗急性或慢性瘙痒症中的作用：方法：在 PubMed、EMBASE、Cochrane Library 和 Web of Science 数据库中对相关随机对照试验进行了系统检索。使用RevMan5.4和R4.3.1进行了带有95% CI的汇总奇数比（OR）分析：对涉及 2,016 名患者的 27 篇文章进行的分析表明，与对照组相比，普瑞巴林/加巴喷丁可显著降低瘙痒发生率（OR，0.30 [CI，0.22-0.4]；I2=1%），改善 VAS（MD，2.76 [CI，0.95-4.57]；I2=98%）和 5-D 评分（MD，3.42 [CI，2.10-4.75]；I2=92%）。不良反应主要包括头晕、嗜睡、恶心呕吐、口干、便秘和焦虑，组间无显著差异（OR，1.08 [CI，0.32-3.59]；I2=76%）：新型抗癫痫药物普瑞巴林和加巴喷丁在治疗瘙痒症方面具有显著的治疗价值，且安全性良好。与抗组胺药和抗抑郁药等常用的瘙痒治疗方法相比，这两种药物是一种很有前景的替代疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of pain and symptom management 医学-临床神经学

CiteScore

8.90

自引率

6.40%

发文量

821

审稿时长

26 days

期刊介绍： The Journal of Pain and Symptom Management is an internationally respected, peer-reviewed journal and serves an interdisciplinary audience of professionals by providing a forum for the publication of the latest clinical research and best practices related to the relief of illness burden among patients afflicted with serious or life-threatening illness.